Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
The genetic flaw causing the immunological condition chronic granulomatous disease can be fixed with the CRISPR technique. But now, scientists from the University of Zurich have demonstrated that there is a chance of unintentionally adding further flaws.
Every year, hundreds of individuals are killed by cobra venom, and an estimated 100,000 more suffer severe injuries from necrosis, which is the loss of bodily tissue and cells and can result in amputation.
The CRISPR technology-based experimental gene editing medication EDIT-101, created by Editas Medicine, was tested for safety and efficacy in the BRILLIANCE study
CAR T cell therapy allows a patient’s T cells to be reprogrammed to identify and eliminate the cancer cells
Senior Investigator Alex Marson, MD, PhD, delved deeply into T-cell DNA to identify certain nucleotides, which are fundamental building blocks of genetic information
Casgevy, one of these treatments, is the first FDA-approved medication to make use of a revolutionary form of genome editing technique
An approval which can transform the treatment technology for β-thalassemia and sickle-cell disease
